Background: Triple negative breast cancer (TNBC), characterized as estrogen receptor (ER), progesteronereceptor (PR) and human epidermal growth factor receptor 2 Her2 negative and accounting for 10-17% of allbreast carcinomas, is only partially responsive to chemotherapy and suffers from a lack of clinically establishedtargeted therapies. The aim of the current study was to evaluate the patterns of treatment and clinicopathologyfigures in Kurdish patients with triple-negative breast cancer, and to compare these to other reports. Materialsand
Methods: Between 2001 and 2014, 950 breast cancer patients were referred to our clinic. There were 74female patients with TNBC, including 70 patients was invasive ductal carcinoma entered into our study. ERand PR positivity was defined as positive immunohistochemical staining in more than 10% of tumor cells.Immunohistochemistry assay with anti-HER2 antibodies was used to identify HER negative (0 and 1+) orpositive (2+ and 3+). HER2 gene amplification was determined by fluorescent in situ hybridization (FISH).Overall survival (OS) was plotted with GraphPad Prism 5 Software using Kaplan-Meier and log-rank testsfor comparison of results.
Results: The mean age in the first diagnosis for 70 patients with triple TNBC andinvasive ductal carcinoma was 49.6 years that range of age was 27-82 years. All of the patients were female.Of 70 patients, 23 patients had metastasis. Thirty-two patients (45.7%) were treated with tamoxifen and 39(55.7%) with radiotherapy. Three-year, 5-year and 10-year OS rates for all patients were 82%, 72% and 64%,respectively.
Conclusions: The OS in our West Iran TNBC patients is less than reported elsewhere. However,treatment with combination of tamoxifen plus radiation increases the OS and reduces the mortality rate.